Recent concepts of antiangiogenic therapy

Surgery Today

Volumn 40, Issue 6, 2010, Pages 494-500

  Konno, Hiroyuki ^a   Yamamoto, Masayoshi ^a   Ohta, Manabu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiangiogenic therapy; Endothelial progenitor cell; Vascular normalization

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; ENDOSTATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANTIANGIOGENIC THERAPY; BLEEDING; BLOOD VESSEL; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; EMBOLISM; ENDOTHELIUM; GASTROINTESTINAL STROMAL TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77953635622     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4150-2     Document Type: Review

References (40)

1. J. Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 4938153
2. T. Kanai H. Konno T. Tanaka M. Baba K. Matsumoto S. Nakamura, et al. 1998 Anti-tumor and anti-metastatic effects of human vascular endothelial growth factor neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice Int J Cancer 77 933 936 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0 1:CAS:528:DyaK1cXltlKkt7s%3D 9714067 (Pubitemid 28378146)
3. H. Konno T. Arai T. Tanaka M. Baba K. Matsumoto T. Kanai, et al. 1998 Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm Jpn J Cancer Res 89 933 939 1:CAS:528:DyaK1cXmsVyrtLo%3D 9818029
4. H. Hurwitz L. Fehrenbacher W. Novotny T. Cartwright J. Hainsworth W. Heim, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
5. H. Takahashi M. Shibuya 2005 The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions Clin Sci 109 227 241 10.1042/CS20040370 1:CAS:528: DC%2BD2MXoslKgu78%3D 16104843 (Pubitemid 41337127)
6. D. Hanahan J. Folkman 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 353 364 10.1016/S0092-8674(00) 80108-7 1:CAS:528:DyaK28XltVSks7s%3D 8756718 (Pubitemid 26272076)
7. R.K. Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D 11533692 (Pubitemid 32937367)
8. M. Milosevic A. Fyles D. Hedley M. Pintilie W. Levin L. Manchul, et al. 2001 Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements Cancer Res 61 6400 6405 1:CAS:528:DC%2BD3MXmsF2jsLs%3D 11522633
9. R.K. Jain R.T. Tong L.L. Munn 2007 Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2729 2735 10.1158/0008-5472.CAN-06-4102 1:CAS:528:DC%2BD2sXivV2nsLw%3D 17363594 (Pubitemid 46548961)
10. C. Miki K. Tanaka Y. Inoue T. Araki M. Ohi Y. Mohri, et al. 2008 Perioperative host-tumor inflammatory interactions: a potential trigger for disease recurrence following a curative resection for colorectal cancer Surg Today 38 579 584 10.1007/s00595-007-3674-6 18612780 (Pubitemid 351977650)
11. F. Winkler S.V. Kozin R.T. Tong S.S. Chae M.F. Booth I. Garkavtsev, et al. 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 553 563 1:CAS:528:DC%2BD2MXktVantw%3D%3D 15607960
12. R.K. Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar 15637262 (Pubitemid 40093472)
13. D. Gao D.J. Nolan A.S. Mellick K. Bambino K. McDonnell V. Mittal 2008 Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis Science 319 195 198 10.1126/science.1150224 1:CAS:528: DC%2BD1cXis1amtA%3D%3D 18187653
14. F. Bertolini Y. Shaked P. Mancuso R.S. Kerbel 2006 The multifaceted circulating endothelial cell in cancer: towards marker and target identification Nat Rev Cancer 6 835 845 10.1038/nrc1971 1:CAS:528:DC%2BD28XhtFWhs7bL 17036040 (Pubitemid 44629895)
15. D. Lyden K. Hattori S. Dias C. Costa P. Blaikie L. Butros, et al. 2001 Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 1194 1201 10.1038/nm1101-1194 1:CAS:528:DC%2BD3MXotlKltLY%3D 11689883 (Pubitemid 33063774)
16. R.N. Kaplan R.D. Riba S. Zacharoulis A.H. Bramley L. Vincent C. Costa, et al. 2005 VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche Nature 438 820 827 10.1038/nature04186 1:CAS:528: DC%2BD2MXht1ynsrnL 16341007 (Pubitemid 41753060)
17. Y. Shaked A. Ciarrocchi M. Franco C.R. Lee S. Man A.M. Cheung, et al. 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313 1785 1787 10.1126/science.1127592 1:CAS:528:DC%2BD28Xpsl2qs74%3D 16990548 (Pubitemid 44454154)
18. D.W. Siemann D.J. Chaplin M.R. Horsman 2004 Vascular-targeting therapies for treatment of malignant disease Cancer 100 2491 2499 10.1002/cncr.20299 1:CAS:528:DC%2BD2cXlsFChsrY%3D 15197790 (Pubitemid 38715753)
19. G.M. Tozer C. Kanthou B.C. Baguley 2005 Disrupting tumour blood vessels Nat Rev Cancer 5 423 435 10.1038/nrc1628 1:CAS:528:DC%2BD2MXks1Gmsr0%3D 15928673 (Pubitemid 40791485)
20. G. Furstenberger R. von Moos R. Lucas B. Thurlimann H.J. Senn J. Hamacher, et al. 2006 Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer Br J Cancer 94 524 531 10.1038/sj.bjc.6602952 1:STN:280:DC%2BD287gsFKntQ%3D%3D 16450002 (Pubitemid 43289756)
21. G. Klement S. Baruchel J. Rak S. Man K. Clark D.J. Hicklin, et al. 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 R15 24 10.1172/JCI8829 1:CAS:528:DC%2BD3cXisFOlurc%3D 10772661
22. A.A. Garcia H. Hirte G. Fleming D. Yang D.D. Tsao-Wei L. Roman, et al. 2008 Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 76 82 10.1200/JCO.2007.12.1939 1:CAS:528:DC%2BD1cXhsVCrsLc%3D 18165643
23. S. Monestiroli P. Mancuso A. Burlini G. Pruneri C. Dell'Agnola A. Gobbi, et al. 2001 Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res 61 4341 4344 1:CAS:528:DC%2BD3MXktlSqu74%3D 11389057
24. P. Mancuso A. Calleri C. Cassi A. Gobbi M. Capillo G. Pruneri, et al. 2003 Circulating endothelial cells as a novel marker of angiogenesis Adv Exp Med Biol 522 83 97 12674213 (Pubitemid 36570529)
25. P. Beaudry J. Force G.N. Naumov A. Wang C.H. Baker A. Ryan, et al. 2005 Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity Clin Cancer Res 11 3514 3522 10.1158/1078-0432.CCR-04-2271 1:CAS:528: DC%2BD2MXjslOqtLk%3D 15867254 (Pubitemid 40627906)
26. P. Mancuso M. Colleoni A. Calleri L. Orlando P. Maisonneuve G. Pruneri, et al. 2006 Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy Blood 108 452 459 10.1182/blood-2005-11-4570 1:CAS:528:DC%2BD28XntFeht78%3D 16543470 (Pubitemid 44061341)
27. Y. Shaked F. Bertolini S. Man M.S. Rogers D. Cervi T. Foutz, et al. 2005 Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis Cancer Cell 7 101 111 1:CAS:528:DC%2BD2MXhsVait7w%3D 15652753
28. A. Sandler R. Gray M.C. Perry J. Brahmer J.H. Schiller A. Dowlati, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer N Engl J Med 355 2542 2550 10.1056/NEJMoa061884 1:CAS:528: DC%2BD28XhtlWqsbzI 17167137 (Pubitemid 44917502)
29. K. Miller M. Wang J. Gralow M. Dickler M. Cobleigh E.A. Perez, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D 18160686
30. B. Ramaswamy A.D. Elias N.T. Kelbick A. Dodley M. Morrow M. Hauger, et al. 2006 Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients Clin Cancer Res 12 3124 3129 10.1158/1078-0432.CCR-05-2603 1:CAS:528:DC%2BD28Xks1Ciurw%3D 16707611 (Pubitemid 43837360)
31. K. Senior 2006 Combination treatment improves breast-cancer survival Lancet Oncol 7 370 10.1016/S1470-2045(06)70682-9 16696166
32. L.M. Ellis D.J. Hicklin 2008 VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 579 591 10.1038/nrc2403 1:CAS:528:DC%2BD1cXovV2lsro%3D 18596824
33. B. Escudier T. Eisen W.M. Stadler C. Szczylik S. Oudard M. Siebels, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 17215530 (Pubitemid 46089673)
34. J.M. Llovet S. Ricci V. Mazzaferro P. Hilgard E. Gane J.F. Blanc, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
35. G.D. Demetri A.T. van Oosterom C.R. Garrett M.E. Blackstein M.H. Shah J. Verweij, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL 17046465 (Pubitemid 44528723)
36. R.J. Motzer T.E. Hutson P. Tomczak M.D. Michaelson R.M. Bukowski O. Rixe, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529 (Pubitemid 46089672)
37. Koehne C, Bajetta E, Lin E, Valle J, Van Cutsem E, Hecht J, et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proc Am Soc Clin Oncol 2007;4033a.
38. Koehne C, Bajetta E, Lin E, Van Cutsem E, Hecht J, Douillard J, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). Proc Am Soc Clin Oncol 2006;3508a.
39. M. Ohta T. Kawabata M. Yamamoto T. Tanaka H. Kikuchi Y. Hiramatsu, et al. 2009 TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model Surg Today 39 1046 1053 10.1007/s00595-009-4020-y 1:CAS:528:DC%2BD1MXhsFanu7fN 19997799
40. M. Yamamoto H. Kikuchi M. Ohta T. Kawabata Y. Hiramatsu K. Kondo, et al. 2008 TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche Cancer Res 68 9754 9762 10.1158/0008-5472.CAN-08-1748 1:CAS:528:DC%2BD1cXhsVegtbjM 19047154